Celltrion
http://
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Celltrion
Celltrion Takes Aim At US Infliximab Market With Subcutaneous Launch
Celltrion has delivered on its long-awaited US launch of its Zymfentra subcutaneous formulation of infliximab, sold in other territories as Remsima SC.
NASH: Madrigal Files Resmetirom In EU While US Action Date Closes In
Resmetirom, which could become the first approved treatment for non-alcoholic steatohepatitis, is among 11 new drugs that the European Medicines Agency has started to review for potential EU approval. Meanwhile, a decision on whether to approve the drug in the US is due on 14 March.
Celltrion Files Tocilizumab In US
Celltrion has become the latest firm to file for a tocilizumab biosimilar in the US, submitting its CT-P47 candidate to the FDA.
Celltrion Reveals 2030 Ambition Amid 80mg High-Concentration Adalimumab Launch
Celltrion has grand ambitions to grow its portfolio and top line by the start of the next decade, as the firm told the recent Annual J.P. Morgan Healthcare Conference.
Company Information
- Industry
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice